J Dent Anesth Pain Med.  2016 Sep;16(3):151-157. 10.17245/jdapm.2016.16.3.151.

Use of a botulinum toxin A in dentistry and oral and maxillofacial surgery

• Park KS
• Lee CH
• Lee JW

• KMID: 2354649
• DOI: http://doi.org/10.17245/jdapm.2016.16.3.151

Abstract

Botulinum toxin (BT) was the first toxin to be used in the history of human medicine. Among the eight known serotypes of this toxin, those currently used in medicine are types A and B. This review article mainly discusses BT type A (BTA) because it is usually used in dentistry including dental anesthesiology and oral and maxillofacial surgery. BTA has been used mainly in the treatment of temporomandibular joint disorder (TMD) and hypertrophy and hyperactivity of the masticatory muscles, along with being a therapeutic option to relieve pain and help in functional recovery from dental and oral and maxillofacial surgery. However, it is currently used broadly for cosmetic purposes such as reducing facial wrinkles and asymmetry. Although the therapeutic effect of BTA is temporary and relatively safe, it is essential to have knowledge about related anatomy, as well as the systemic and local adverse effects of medications that are applied to the face.

Keyword

Botulinum toxin; Botulinum toxin, type A; Dentistry; Oral and Maxillofacial Surgeons

MeSH Terms

Anesthesiology
Botulinum Toxins*
Dentistry*
Humans
Hypertrophy
Masticatory Muscles
Oral and Maxillofacial Surgeons
Serogroup
Surgery, Oral*
Temporomandibular Joint Disorders
Botulinum Toxins

Reference

1. Kerner J. Vergiftung durch verdorbene würste. Tübinger Blätter für Naturwissenschaften und Arzneykunde. 1817. p. 25.

2. Lu DW, Lippitz J. Complications of botulinum neurotoxin. Dis Mon. 2009; 55:198–211.

3. van Ermengem E. A new anaerobic bacillus and its relation to botulism. Rev Infect Dis. 1979; 1:701–719.

4. Burgen AS, Dickens F, Zatman LJ. The action of botulinum toxin on the neuro-muscular junction. J Physiol. 1949; 109:10–24.

5. Erbguth FJ. From poison to remedy: The chequered history of botulinum toxin. J Neural Transm (Vienna). 2008; 115:559–565.

6. Scott A. Botulinum toxin injection to correct strabism. Trans Am Ophthalmol Soc. 1979; 79:924–927.

7. Scott AB. Botulinum toxin injection of eye muscles to correct strabismus. Trans Am Ophthalmol Soc. 1981; 79:734–770.

8. Carruthers JD, Carruthers JA. Treatment of glabellar frown lines with c. Botulinum-a exotoxin. J Dermatol Surg Oncol. 1992; 18:17–21.

9. Blitzer A, Brin MF, Keen MS, Aviv JE. Botulinum toxin for the treatment of hyperfunctional lines of the face. Arch Otolaryngol Head Neck Surg. 1993; 119:1018–1022.

10. Hoffman WY. Reanimation of the paralyzed face. Otolaryngol Clin North Am. 1992; 25:649–667.

11. Shaari CM, George E, Wu BL, Biller HF, Sanders I. Quantifying the spread of botulinum toxin through muscle fascia. Laryngoscope. 1991; 101:960–964.

12. Jankovic J, Brin MF. Therapeutic uses of botulinum toxin. N Engl J Med. 1991; 324:1186–1194.

13. Fulton JE. Botulinum toxin. The Newport Beach experience. Dermatol Surg. 1998; 24:1219–1224.

14. Osako M, Keltner JL. Botulinum-a toxin (oculinum) in ophthalmology. Surv Ophthalmol. 1991; 36:28–46.

15. Carruthers A, Kiene K, Carruthers J. Botulinum a exotoxin use in clinical dermatology. J Am Acad Dermatol. 1996; 34:788–797.

16. Kao I, Drachman DB, Price DL. Botulinum toxin: Mechanism of presynaptic blockade. Science. 1976; 193:1256–1258.

17. Simpson LL. The origin, structure, and pharmacological activity of botulinum toxin. Pharmacol Rev. 1981; 33:155–188.

18. Jaspers GW, Pijpe J, Jansma J. The use of botulinum toxin type a in cosmetic facial procedures. Int J Oral Maxillofac Surg. 2011; 40:127–133.

19. de Maio M. Therapeutic uses of botulinum toxin: From facial palsy to autonomic disorders. Expert Opin Biol Ther. 2008; 8:791–798.

20. Bhogal PS, Hutton A, Monaghan A. A review of the current uses of botox for dentally-related procedures. Dent Update. 2006; 33:165–168.

21. Gracco A, Tracey S. Botox and the gummy smile. Prog Orthod. 2010; 11:76–82.

22. Niamtu J. Botulinum toxin a: A review of 1,085 oral and maxillofacial patient treatments. J Oral Maxillofac Surg. 2003; 61:317–324.

23. Hegedus F, Diecidue R, Taub D, Nyirady J. Non-surgical treatment modalities of facial photodamage: Practical knowledge for the oral and maxillofacial professional. Int J Oral Maxillofac Surg. 2006; 35:389–398.

24. Fagien S, Brandt FS. Primary and adjunctive use of botulinum toxin type a (botox) in facial aesthetic surgery - beyond the glabella. Clin Plast Surg. 2001; 28:127–148.

25. Frampton JE, Easthope SE. Botulinum toxin a (botox((r)) cosmetic) a review of its use in the treatment of glabellar frown lines. Am J Clin Dermatol. 2003; 4:709–725.

26. Niamtu J. Aesthetic uses of botulinum toxin a. J Oral Maxillofac Surg. 1999; 57:1228–1233.

27. Carruthers A. Facial aesthetic enhancement educational initiative. Chicago, IL: Faculty Training;2001. p. 13–15.

28. Bentsianov B, Francis A, Blitzer A. Botulinum toxin treatment of temporomandibular disorders, masseteric hypertrophy, and cosmetic masseter reduction. Oper Tech Otorhinolaryngol-Head Neck Surg. 2004; 15:110–113.

29. Hoque A, McAndrew M. Use of botulinum toxin in dentistry. N Y State Dent J. 2009; 75:52–55.

30. Ihde SK, Konstantinovic VS. The therapeutic use of botulinum toxin in cervical and maxillofacial conditions: An evidence-based review. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007; 104:e1–e11.

31. Lee CJ, Kim SG, Kim YJ, Han JY, Choi SH, Lee SI. Electrophysiologic change and facial contour following botulinum toxin a injection in square faces. Plast Reconstr Surg. 2007; 120:769–778.

32. Moore AP, Wood GD. The medical management of masseteric hypertrophy with botulinum toxin type a. Br J Oral Maxillofac Surg. 1994; 32:26–28.

33. Kim HS, Yun PY, Kim YK. A clinical evaluation of botulinum toxin-a injections in the temporomandibular disorder treatment. Maxillofac Plast Reconstr Surg. 2016; 38:5.

34. Ellies M, Laskawi R, Tormahlen G, Gotz W. The effect of local injection of botulinum toxin a on the parotid gland of the rat: An immunohistochemical and morphometric study. J Oral Maxillofac Surg. 2000; 58:1251–1256.

35. Ahuja RB, Chatterjee P. Contemporary solutions for the treatment of facial nerve paralysis. Plast Reconstr Surg. 2016; 137:482e–483e.

36. Sinclair CF, Gurey LE, Blitzer A. Oromandibular dystonia: Long-term management with botulinum toxin. Laryngoscope. 2013; 123:3078–3083.

37. Freund B, Schwartz M. Temporal relationship of muscle weakness and pain reduction in subjects treated with botulinum toxin a. J Pain. 2003; 4:159–165.

38. Moore AP, Wood G. Medical treatment of recurrent temporomandibular joint dislocation using botulinum toxin a. Br Dent J. 1996; 183:415–417.

39. Shorey CW, Campbell JH. Dislocation of the temporomandibular joint. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2000; 89:662–668.

40. Ziegler CM, Haag C, Muhling J. Treatment of recurrent temporomandibular joint dislocation with intramuscular botulinum toxin injection. Clin Oral Investig. 2003; 7:52–55.

41. Freund B, Schwartz M, Symington JM. The use of botulinum toxin for the treatment of temporomandibular disorders: Preliminary findings. J Oral Maxillofac Surg. 1999; 57:916–920.

42. Freund BJ, Schwartz M. Relief of tension-type headache symptoms in subjects with temporomandibular disorders treated with botulinum toxin-a. Headache. 2002; 42:1033–1037.

43. Bakke M, Moller E, Werdelin LM, Dalager T, Kitai N, Kreiborg S. Treatment of severe temporomandibular joint clicking with botulinum toxin in the lateral pterygoid muscle in two cases of anterior disc displacement. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005; 100:693–700.

44. Daelen B, Thorwirth V, Koch A. Treatment of recurrent dislocation of the temporomandibular joint with type a botulinum toxin. Int J Oral Maxillofac Surg. 1997; 26:458–460.

45. Ellis MF, Daniell M. An evaluation of the safety and efficacy of botulinum toxin type a (botox) when used to produce a protective ptosis. Clin Exp Ophthalmol. 2001; 29:394–399.

46. Sadiq SA, Downes RN. A clinical algorithm for the management of facial nerve palsy from an oculoplastic perspective. Eye. 1998; 12:219–223.

47. Armstrong MW, Mountain RE, Murray JA. Treatment of facial synkinesis and facial asymmetry with botulinum toxin type a following facial nerve palsy. Clin Otolaryngol Allied Sci. 1996; 21:15–20.

48. Freund BJ, Schwartz M. Intramuscular injection of botulinum toxin as an adjunct to arthrocentesis of the temporomandibular joint: Preliminary observations. Br J Oral Maxillofac Surg. 2003; 41:351–352.

49. Majid OW. Clinical use of botulinum toxins in oral and maxillofacial surgery. Int J Oral Maxillofac Surg. 2010; 39:197–207.

50. McKellar G, Lorentz I. The use of botulinum-toxin in the treatment of oromandibular dystonias and fractures of the mandibular condyle. Aust NZJ Med. 1992; 22:428.

51. Capaccio P, Cuccarini V, Benicchio V, Minorati D, Spadari F, Ottaviani F. Treatment of iatrogenic submandibular sialocele with botulinum toxin. Case report. Br J Oral Maxillofac Surg. 2007; 45:415–417.

52. Drobik C, Laskawi R. Frey's syndrome: Treatment with botulinum toxin. Acta Otolaryngol. 1995; 115:459–461.

53. Lagalla G, Millevolte M, Capecci M, Provinciali L, Ceravolo MG. Botulinum toxin type a for drooling in parkinson's disease: A double-blind, randomized, placebo-controlled study. Mov Disord. 2006; 21:704–707.

54. Laskawi R, Drobik C, Schonebeck C. Up-to-date report of botulinum toxin type a treatment in patients with gustatory sweating (frey's syndrome). Laryngoscope. 1998; 108:381–384.

55. Ondo WG, Hunter C, Moore W. A double-blind placebo-controlled trial of botulinum toxin b for sialorrhea in parkinson's disease. Neurology. 2004; 62:37–40.

56. Archana M. Toxin yet not toxic: Botulinum toxin in dentistry. Saudi Dent J. 2015; 28:63–69.

57. Brin MF, Boodhoo TI, Pogoda JM, James LM, Demos G, Terashima Y, et al. Safety and tolerability of onabotulinumtoxina in the treatment of facial lines: A meta-analysis of individual patient data from global clinical registration studies in 1678 participants. J Am Acad Dermatol. 2009; 61:961–970.

58. Berry MG, Stanek JJ. Botulinum neurotoxin a: A review. J Plast Reconstr Aesthet Surg. 2012; 65:1283–1291.

59. Adelson RT. Botulinum neurotoxins: Fundamentals for the facial plastic surgeon. Am J Otolaryngol. 2007; 28:260–266.

60. Cote TR, Mohan AK, Polder JA, Walton MK, Braun MM. Botulinum toxin type a injections: Adverse events reported to the us food and drug administration in therapeutic and cosmetic cases. J Am Acad Dermatol. 2005; 53:407–415.

61. Critchfield J. Considering the immune response to botulinum toxin. Clin J Pain. 2002; 18:S133–S141.

62. Kessler KR, Skutta M, Benecke R. Long-term treatment of cervical dystonia with botulinum toxin a: Efficacy, safety, and antibody frequency. German dystonia study group. J Neurol. 1999; 246:265–274.

63. Naumann M, Albanese A, Heinen F, Molenaers G, Relja M. Safety and efficacy of botulinum toxin type a following long-term use. Eur J Neurol. 2006; 13:35–40.

64. Dressler D, Eleopra R. Clinical use of non-a botulinum toxins: Botulinum toxin type b. Neurotox Res. 2006; 9:121–125.